Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial-Reference-Cited by-同舟云学术

Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial

Published:2014-06 Issue:7 Volume:15 Page:713-721
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Gregorc Vanesa,Novello Silvia,Lazzari Chiara,Barni Sandro,Aieta Michele,Mencoboni Manlio,Grossi Francesco,Pas Tommaso De,de Marinis Filippo,Bearz Alessandra,Floriani Irene,Torri Valter,Bulotta Alessandra,Cattaneo Angela,Grigorieva Julia,Tsypin Maxim,Roder Joanna,Doglioni Claudio,Levra Matteo Giaj,Petrelli Fausto,Foti Silvia,Viganò Mariagrazia,Bachi Angela,Roder Heinrich

Publisher

Elsevier BV

Subject

Oncology

Reference23 articles.

1. Gefitinib or carboplatin paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med,2009

2. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial;Rosell;Lancet Oncol,2012

3. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR Mutations;Sequist;J Clin Oncol,2013

4. Meta-analysis of EGFR kinase inhibitors: not always greater than the sum of its parts;Cardarella;J Natl Cancer Inst,2013

5. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy;Shepherd;J Clin Oncol,2000

Cited by 148 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A review on trends in development and translation of omics signatures in cancer;Computational and Structural Biotechnology Journal;2024-12

2. The antitumor activity of osimertinib plus palbociclib in non-small cell lung cancer patient-derived xenograft (PDX)/2D/3D culture models harboring EGFR amplification and CDKN2A/2B homozygous deletions;Neoplasia;2024-11

3. Molecular and translational biology of the blood-based VeriStrat® proteomic test used in cancer immunotherapy treatment guidance;Journal of Mass Spectrometry and Advances in the Clinical Lab;2023-11

4. Increased c‑SRC expression is involved in acquired resistance to lenvatinib in hepatocellular carcinoma;Oncology Letters;2023-10-25

5. Evaluation of pre-diagnostic blood protein measurements for predicting survival after lung cancer diagnosis;eBioMedicine;2023-06